Jennison Associates
BMRN icon

Jennison Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History

Jennison Associates’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-50,000
Closed -$4.38M – 672
2020
Q4 		$4.38M Buy
+50,000
New +$3.96M ﹤0.01% 465
2020
Q1 		– Sell
-60,000
Closed -$5.07M – 631
2019
Q4 		$5.07M Buy
+60,000
New +$4.53M 0.01% 431

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jennison Associates's BMRN Position: Q1 2024 in Review

Jennison Associates sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 332,018 shares — an estimated $32M sold.

Jennison Associates first reported a position in BMRN in Q2 2013 and held it in 40 quarters. The position peaked at $1.2B in Q2 2017. 561 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

  • Jennison Associates reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Jennison Associates sold 332,018 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $32M.
  • Jennison Associates first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 40 quarters.
  • Jennison Associates's BioMarin Pharmaceuticals position peaked at $1.2B in Q2 2017.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Jennison Associates's 13F filing for Q1 2024, filed 2 May 2024.